{"id":"NCT01005888","sponsor":"Shire","briefTitle":"C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks","officialTitle":"LEVP2005-1/Part B: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) as Prophylactic Treatment to Prevent HAE Attacks","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-03-14","primaryCompletion":"2007-08-22","completion":"2007-08-22","firstPosted":"2009-11-02","resultsPosted":"2010-06-03","lastUpdate":"2021-06-11"},"enrollment":26,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Hereditary Angioedema"],"interventions":[{"type":"BIOLOGICAL","name":"C1 esterase inhibitor [human] (C1INH-nf)","otherNames":[]},{"type":"DRUG","name":"Placebo (saline)","otherNames":[]}],"arms":[{"label":"C1INH-nf First, then Placebo","type":"EXPERIMENTAL"},{"label":"Placebo First, then C1INH-nf","type":"EXPERIMENTAL"}],"summary":"The study objective was to determine the safety and efficacy of C1INH-nf for the prevention of acute HAE attacks.","primaryOutcome":{"measure":"Number of Hereditary Angioedema (HAE) Attacks During Each Prophylactic Therapy Period","timeFrame":"12 weeks","effectByArm":[{"arm":"C1INH-nf","deltaMin":6.1,"sd":5.43},{"arm":"Placebo","deltaMin":12.7,"sd":4.8}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":["36326435","25295804","23312695","20818886"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Cough","Pruritus","Rash","Chest discomfort","Pyrexia"]}}